{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:45:27Z","timestamp":1775155527799,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:p>Adrenal cortical carcinoma (ACC) is rare in clinical practice, and its prognosis and treatment have not been systematically studied. This study aimed to investigate the prognostic factors and impact of treatment strategies on overall survival (OS) and cancer-specific survival (CSS) in patients with ACC, using Surveillance, Epidemiology, and End Results registry data. Patient\u2019s data for ACC pathologically diagnosed between 2000 and 2021 were identified from Surveillance, Epidemiology, and End Results database. The Kaplan\u2013Meier method was used to assess OS and CSS. While Cox proportional hazards regression analysis was used to evaluate the risk predictors of OS and CSS, the effects of surgery, chemotherapy, and radiotherapy on OS and CSS were also assessed using directed acyclic graphs-guided multivariate Cox regression model. A total of 444 patients with ACC were enrolled. The median OS and CSS in this cohort were 25 and 30 months, respectively. The OS at 1, 2, and 5 years were 62.7%, 50.2%, and 31.5%, respectively, while the CSS at 1, 2, and 5 years were 66.6%, 54.8%, and 37.2%, respectively. Patients with\u2005\u2265\u200553 years old, pathological grade \u2162\/\u2163, clinical stage \u2162\/\u2163, T3\/4, N1, M1, and none receiving the therapy of surgery or radiation had worse survival. Old age, worse clinical stages, poor pathological grade, distant metastasis, no surgical treatment, and no radiation therapy were risk predictors of OS and CSS. In addition, receiving surgery or radiation therapy improved OS and CSS in the directed acyclic graph-guided multivariate Cox regression model. ACC has malignant behavior and a relatively poor prognosis. Old age, poor pathological grades, late clinical stages, and advanced tumor node metastasis classification indicate poor survival. While surgical resection of tumor lesions is one of the effective treatments, which can improve the outcome of patients with ACC, radiation therapy may be a palliative and beneficial treatment for patients with advanced disease.<\/jats:p>","DOI":"10.1097\/md.0000000000042831","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T10:00:56Z","timestamp":1753956056000},"page":"e42831","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic factors and treatment outcomes in patients with adrenal cortical carcinoma: A registry-based study"],"prefix":"10.1097","volume":"104","author":[{"given":"Tao","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linghui","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3616-5520","authenticated-orcid":false,"given":"Xiaoyuan","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251014","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma.","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"R2-20251014","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg"},{"key":"R3-20251014","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.soc.2015.08.011","article-title":"Surgical management of adrenocortical carcinoma: an evidence-based approach.","volume":"25","author":"Datta","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"key":"R4-20251014","doi-asserted-by":"crossref","first-page":"961650","DOI":"10.3389\/fendo.2022.961650","article-title":"Pediatric adrenocortical carcinoma.","volume":"13","author":"Ilanchezhian","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R5-20251014","doi-asserted-by":"crossref","first-page":"811293","DOI":"10.3389\/fendo.2021.811293","article-title":"Future directions in diagnosis, prognosis and disease monitoring of adrenocortical carcinoma: novel non-invasive biomarkers.","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R6-20251014","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/bjs.9743","article-title":"Diagnosis, treatment and outcome of adrenocortical cancer.","volume":"102","author":"Mihai","year":"2015","journal-title":"Br J Surg"},{"key":"R7-20251014","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.21037\/gs-22-274","article-title":"Change of treatment modality and outcomes of adrenocortical carcinoma: a retrospective review of single tertiary center experience over 24 years.","volume":"11","author":"Rah","year":"2022","journal-title":"Gland Surg"},{"key":"R8-20251014","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12022-023-09760-6","article-title":"Prognostic value of microscopic tumor necrosis in adrenal cortical carcinoma.","volume":"34","author":"Luconi","year":"2023","journal-title":"Endocr Pathol"},{"key":"R9-20251014","doi-asserted-by":"crossref","first-page":"1184607","DOI":"10.3389\/fmed.2023.1184607","article-title":"Construction of a novel clinical nomogram to predict cancer-specific survival in patients with primary malignant adrenal tumors: a large population-based retrospective study.","volume":"10","author":"Li","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R10-20251014","first-page":"50","article-title":"How to use the Surveillance, Epidemiology, and End Results (SEER) data: research design and methodology.","volume":"10","author":"Che","year":"2023","journal-title":"Mil Med Res"},{"key":"R11-20251014","doi-asserted-by":"crossref","first-page":"810096","DOI":"10.3389\/fonc.2022.810096","article-title":"Impact of treatment modalities on prognosis in patients with renal collecting duct carcinoma: a population-based study.","volume":"12","author":"Qian","year":"2022","journal-title":"Front Oncol"},{"key":"R12-20251014","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11912-019-0773-7","article-title":"Management of adrenocortical carcinoma.","volume":"21","author":"Jasim","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"R13-20251014","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors.","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"R14-20251014","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00001622-200401000-00004","article-title":"Adrenocortical cancer: recent clinical and molecular advances.","volume":"16","author":"Sidhu","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"R15-20251014","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/BF03346675","article-title":"Response to radiation therapy in adrenocortical carcinoma.","volume":"33","author":"Hermsen","year":"2010","journal-title":"J Endocrinol Invest"},{"key":"R16-20251014","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4158\/DSCR-2020-0567","article-title":"American Association of Clinical Endocrinology Disease State Clinical Review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach.","volume":"26","author":"Kiseljak-Vassiliades","year":"2020","journal-title":"Endocr Pract"},{"key":"R17-20251014","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0022-5347(05)64023-2","article-title":"Adrenocortical carcinoma: diagnosis, evaluation and treatment.","volume":"169","author":"Ng","year":"2003","journal-title":"J Urol"},{"key":"R18-20251014","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.2147\/OTT.S147352","article-title":"Primary site surgery for metastatic adrenocortical carcinoma improves survival outcomes: an analysis of a population-based database.","volume":"10","author":"Wang","year":"2017","journal-title":"Onco Targets Ther"},{"key":"R19-20251014","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.surg.2014.08.047","article-title":"Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease.","volume":"156","author":"Livhits","year":"2014","journal-title":"Surgery"},{"key":"R20-20251014","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.ijrobp.2010.04.030","article-title":"Adjuvant and definitive radiotherapy for adrenocortical carcinoma.","volume":"80","author":"Sabolch","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R21-20251014","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00129039-200312000-00009","article-title":"Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas.","volume":"11","author":"Ghorab","year":"2003","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R22-20251014","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clgc.2021.03.009","article-title":"Stage presentation, care patterns, treatment outcomes, and impact of radiotherapy on overall survival for adrenocortical carcinoma.","volume":"19","author":"Thomas","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"R23-20251014","doi-asserted-by":"crossref","first-page":"791.e1","DOI":"10.1016\/j.urolonc.2021.06.019","article-title":"Identification of oncological characteristics associated with improved overall survival in patients with adrenocortical carcinoma treated with adjuvant radiation therapy: insights from the National Cancer Database.","volume":"39","author":"Ginsburg","year":"2021","journal-title":"Urol Oncol"},{"key":"R24-20251014","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13014-020-01533-3","article-title":"Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis.","volume":"15","author":"Zhu","year":"2020","journal-title":"Radiat Oncol"},{"key":"R25-20251014","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1210\/jc.2019-00029","article-title":"Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma.","volume":"104","author":"Gharzai","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-20251014","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41416-022-02082-0","article-title":"Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma.","volume":"128","author":"Kimpel","year":"2023","journal-title":"Br J Cancer"},{"key":"R27-20251014","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1530\/ERC-13-0150","article-title":"Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells.","volume":"20","author":"Poli","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"R28-20251014","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","article-title":"Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1-reductase, explaining the need for personalized glucocorticoid and androgen replacement.","volume":"98","author":"Chortis","year":"2013","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T17:02:08Z","timestamp":1760461328000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":28,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042831","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}